Ruth Frampton

670 total citations
16 papers, 548 citations indexed

About

Ruth Frampton is a scholar working on Pathology and Forensic Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Ruth Frampton has authored 16 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in Ruth Frampton's work include Vitamin D Research Studies (5 papers), Diabetes Treatment and Management (4 papers) and Diabetes Management and Research (4 papers). Ruth Frampton is often cited by papers focused on Vitamin D Research Studies (5 papers), Diabetes Treatment and Management (4 papers) and Diabetes Management and Research (4 papers). Ruth Frampton collaborates with scholars based in Australia. Ruth Frampton's co-authors include T. John Martin, V. P. Michelangeli, David M. Findlay, John A. Eisman, John A. Eisman, T. John Martin, I. MacIntyre, Jane M. Moseley, T. R. Bradley and Nicola C. Partridge and has published in prestigious journals such as Diabetes Care, Biochemical and Biophysical Research Communications and FEBS Letters.

In The Last Decade

Ruth Frampton

14 papers receiving 505 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruth Frampton Australia	7	239	217	170	154	90	16	548
Prem P. Dwivedi Australia	12	302 1.3×	222 1.0×	169 1.0×	52 0.3×	113 1.3×	20	606
Maura Simboli-Campbell Canada	8	282 1.2×	164 0.8×	179 1.1×	129 0.8×	46 0.5×	10	456
Joel J. Bergh United States	10	90 0.4×	440 2.0×	159 0.9×	111 0.7×	337 3.7×	11	877
Pilar Blay Spain	13	133 0.6×	384 1.8×	199 1.2×	111 0.7×	78 0.9×	26	735
C. Andrew Powers United States	16	41 0.2×	288 1.3×	268 1.6×	138 0.9×	246 2.7×	36	849
Lina S. Correa-Cerro Mexico	10	90 0.4×	357 1.6×	171 1.0×	26 0.2×	117 1.3×	16	564
Mark Van Camp Belgium	11	309 1.3×	309 1.4×	158 0.9×	140 0.9×	59 0.7×	12	641
Loan Nguyen‐Yamamoto Canada	13	193 0.8×	253 1.2×	173 1.0×	188 1.2×	51 0.6×	13	651
Y. Terashima Japan	13	149 0.6×	256 1.2×	86 0.5×	213 1.4×	22 0.2×	35	701
Sharon Amir Israel	12	146 0.6×	340 1.6×	70 0.4×	107 0.7×	29 0.3×	17	636

Countries citing papers authored by Ruth Frampton

Since Specialization

Citations

This map shows the geographic impact of Ruth Frampton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Frampton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Frampton more than expected).

Fields of papers citing papers by Ruth Frampton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Frampton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Frampton. The network helps show where Ruth Frampton may publish in the future.

Co-authorship network of co-authors of Ruth Frampton

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Frampton. A scholar is included among the top collaborators of Ruth Frampton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Frampton. Ruth Frampton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Greenfield, Jerry R., et al.. (2025). Use of Cardioprotective Adjuncts in Type 1 Diabetes. Diabetes Therapy. 16(2). 145–148. 1 indexed citations

Frampton, Ruth, et al.. (2025). Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends in Endocrinology and Metabolism. 37(2). 135–150.

Frampton, Ruth, et al.. (2025). Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Diabetes Care. 49(1). 161–170.

Frampton, Ruth, et al.. (2024). Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double‐blinded randomised placebo‐controlled trial. Diabetic Medicine. 41(10). e15377–e15377. 6 indexed citations

Frampton, Ruth, et al.. (2015). A pilot study of factors associated with glycaemic control in adults with Type 1 diabetes mellitus on insulin pump therapy. Diabetic Medicine. 33(2). 231–234. 3 indexed citations

Schneider, Hans G., V. P. Michelangeli, Ruth Frampton, et al.. (1992). Transforming growth factor-beta modulates receptor binding of calciotropic hormones and G protein-mediated adenylate cyclase responses in osteoblast-like cells.. Endocrinology. 131(3). 1383–1389. 33 indexed citations

Frampton, Ruth, Helen A. Jonas, & Richard G. Larkins. (1991). Increased secretion of insulin-like growth factor-binding proteins and decreased secretion of insulin-like growth factor-II by muscle from growth-retarded neonatal rats. Journal of Endocrinology. 130(1). 33–42. 5 indexed citations

MacMahon, R.A., et al.. (1990). Effect on the Fetus of Infusing a Commercial Amino Acid Preparation into a Pregnant Sheep. Neonatology. 57(3-4). 231–237. 6 indexed citations

Frampton, Ruth, et al.. (1986). Changes in Plasma Amino Acids in the Developing Chick. Neonatology. 50(3). 154–159. 1 indexed citations

10.

Eisman, John A., et al.. (1984). 1α,25-Dihydroxyvitamin D₃Specifically Induces Its Own Metabolism in a Human Cancer Cell Line. Endocrinology. 114(4). 1225–1231. 21 indexed citations

11.

Eisman, John A., Larry J. Suva, & Ruth Frampton. (1984). 1,25‐DIHYDROXYVITAMIN D₃ AND BREAST CANCER*. Australian and New Zealand Journal of Surgery. 54(1). 17–20. 2 indexed citations

12.

Frampton, Ruth, Larry J. Suva, J. A. Eisman, et al.. (1982). Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.. PubMed. 42(3). 1116–9. 115 indexed citations

13.

Findlay, David M., V. P. Michelangeli, John A. Eisman, et al.. (1980). Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines.. PubMed. 40(12). 4764–7. 103 indexed citations

14.

Partridge, Nicola C., Ruth Frampton, John A. Eisman, et al.. (1980). Receptors for 1,25(OH)₂‐vitamin D₃ enriched in cloned osteoblast‐like rat osteogenic sarcoma cells. FEBS Letters. 115(1). 139–142. 147 indexed citations

15.

Eisman, John A., I. MacIntyre, T. John Martin, Ruth Frampton, & R.J.B. King. (1980). NORMAL AND MALIGNANT BREAST TISSUE IS A TARGET ORGAN FOR 1, 25‐(OH)₂ VITAMIN D₃. Clinical Endocrinology. 13(3). 267–272. 53 indexed citations

16.

Eisman, John A., et al.. (1980). 1,25-dihydroxyvitamin D3 receptor in a cultured human breast cancer cell line (MCF 7 cells). Biochemical and Biophysical Research Communications. 93(1). 9–15. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact